Cyclophosphamide Monohydrate

Catalog No.S2057 Batch:S205707

Technical Data

Formula	C₇H₁₅Cl₂N₂O₂P.H₂O
Molecular Weight	279.1	CAS No.	6055-19-2
Solubility (25°C)*	In vitro	DMSO	56 mg/mL (200.64 mM)
		Water	56 mg/mL (200.64 mM)
		Ethanol	56 mg/mL (200.64 mM)
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description	Cyclophosphamide Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA, shown to crosslink DNA, causing strand breakage and inducing mutations.
In vitro	Cyclophosphamide (CY) is a chemotherapeutic agent with a dose-dependent, bimodal effect on the immune system. Cyclophosphamide treatment enhances apoptosis and decreases homeostatic proliferation of regulatory T cells. Cyclophosphamide downregulates the expression of GITR and FoxP3, which are involved in the suppressive activity of T(REGs).^[1] Cyclophosphamide increases CYP3A4, CYP2C8, and CYP2C9 protein levels in primary human hepatocyte cultures, which thereby enhances their own rates of 4-hydroxylation in the cultured hepatocytes. ^[2] Cyclophosphamide has produced mutations in base-pair substituting strains of Salmonella tryphimurium in the presence of metabolic activation, but it has been shown to be negative in the E. coli chromotest. Cyclophosphamide has been shown to produce gene mutations, chromosome aberrations, micronuclei and sister chromatid exchanges in a variety of cultured cells in the presence of metabolic activation as well as sister chromatid exchanges without metabolic activation. ^[3]
In vivo	Cyclophosphamide has also produced chromosome damage and micronuclei in rats, mice and Chinese hamsters, and gene mutations in the mouse spot test and in the transgenic lacZ construct of Muta Mouse. ^[3] Cyclophosphamide, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhances the vaccine's potential to delay tumor growth in neu transgenic mice. Cyclophosphamide mediates its effects by enhancing the efficacy of the vaccine rather than via a direct cytolytic effect on cancer cells. ^[4]

Description

Cyclophosphamide Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA, shown to crosslink DNA, causing strand breakage and inducing mutations.

In vitro

Cyclophosphamide (CY) is a chemotherapeutic agent with a dose-dependent, bimodal effect on the immune system. Cyclophosphamide treatment enhances apoptosis and decreases homeostatic proliferation of regulatory T cells. Cyclophosphamide downregulates the expression of GITR and FoxP3, which are involved in the suppressive activity of T(REGs).^[1]

Cyclophosphamide increases CYP3A4, CYP2C8, and CYP2C9 protein levels in primary human hepatocyte cultures, which thereby enhances their own rates of 4-hydroxylation in the cultured hepatocytes. ^[2]

Cyclophosphamide has produced mutations in base-pair substituting strains of Salmonella tryphimurium in the presence of metabolic activation, but it has been shown to be negative in the E. coli chromotest. Cyclophosphamide has been shown to produce gene mutations, chromosome aberrations, micronuclei and sister chromatid exchanges in a variety of cultured cells in the presence of metabolic activation as well as sister chromatid exchanges without metabolic activation. ^[3]

In vivo

Cyclophosphamide has also produced chromosome damage and micronuclei in rats, mice and Chinese hamsters, and gene mutations in the mouse spot test and in the transgenic lacZ construct of Muta Mouse. ^[3]

Cyclophosphamide, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhances the vaccine's potential to delay tumor growth in neu transgenic mice. Cyclophosphamide mediates its effects by enhancing the efficacy of the vaccine rather than via a direct cytolytic effect on cancer cells. ^[4]

Protocol (from reference)

Cell Assay:^{^[5]}	Cell lines SUP-T1 cells Concentrations 5.84 pM Incubation Time 3 h Method Cells were treated with indicated concentrations of drug.
Animal Study:^{^[6]}	Animal Models Female MRL/lpr mice Dosages 10 mg/kg Administration i.p.

References

+ Expand

Customer Product Validation

: , , Cancer Res, 2013, 73(20):6310-22.

Selleck's Cyclophosphamide Monohydrate has been cited by 35 publications

Drug-resistant profiles of extracellular vesicles predict therapeutic response in TNBC patients receiving neoadjuvant chemotherapy [ BMC Cancer, 2024, 24(1):185]	PubMed: 38326737
A semiconductor 96-microplate platform for electrical-imaging based high-throughput phenotypic screening [ Nat Commun, 2023, 14(1):7576]	PubMed: 37990016
Patient- and xenograft-derived organoids recapitulate pediatric brain tumor features and patient treatments [ EMBO Mol Med, 2023, 15(12):e18199]	PubMed: 38037472
Targeting the DNA Damage Response to Increase Anthracycline-Based Chemotherapy Cytotoxicity in T-Cell Lymphoma [ Int J Mol Sci, 2022, 23(7)3834]	PubMed: 35409194
The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy [ Transl Oncol, 2022, 15(1):101287]	PubMed: 34808461
Establishment and Characterization of NCC-PMP1-C1: A Novel Patient-Derived Cell Line of Metastatic Pseudomyxoma Peritonei [ J Pers Med, 2022, 12(2)258]	PubMed: 35207746
Establishment and characterization of NCC-UPS4-C1: a novel cell line of undifferentiated pleomorphic sarcoma from a patient with Li-Fraumeni syndrome [ Hum Cell, 2022, 10.1007/s13577-022-00671-y]	PubMed: 35118583
Cyclophosphamide-induced GPX4 degradation triggers parthanatos by activating AIFM1 [ Biochem Biophys Res Commun, 2022, 606:68-74]	PubMed: 35339754
Glutathione peroxidase 4-regulated neutrophil ferroptosis induces systemic autoimmunity [ Nat Immunol, 2021, 22(9):1107-1117]	PubMed: 34385713
Automated evaluation of tumor spheroid behavior in 3D culture using deep learning-based recognition [ Biomaterials, 2021, 272:120770]	PubMed: 33798957

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.